---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-068958"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2022-06-07T23:59:59+00:00"
generated_at: "2026-06-25T03:58:35.557276+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics interim CSO Glenn Pierce resigns as planned, enters consulting agreement; shareholders re-elect him

## Summary
- Glenn Pierce resigned as Interim CSO effective June 2, 2022, after serving in the role since June 2021 on a part-time basis.
- On June 6, Pierce signed a consulting agreement with Voyager capped at $120,000, valid until June 5, 2023, for transition services.
- At the June 6 annual meeting, Pierce was re-elected as Class I director with 21,014,996 votes (88.9% of votes cast).
- Shareholders approved say-on-pay with 23,447,480 votes and ratified Ernst & Young as auditor with 30,505,725 votes.
- Todd Carter, SVP Research, assumed increased R&D responsibilities starting June 3, reporting to CEO; search for a CSO is underway.

## SEC filing metadata
- accession: 0001104659-22-068958
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2022-06-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465922068958/0001104659-22-068958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465922068958/tm2217868d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-068958
- JSON: https://secwatch.observer/filing/0001104659-22-068958.json
- Plain text: https://secwatch.observer/filing/0001104659-22-068958.txt

## Key facts
- Executive change
  Glenn Pierce resigned as Interim Chief Scientific Officer at Voyager Therapeutics, Inc..
  - Action: resigned
  - Role: Interim Chief Scientific Officer
  source text: On June 2, 2022, Glenn Pierce, M.D., Ph.D. provided notice to Voyager Therapeutics, Inc. (“Voyager”) of his resignation as Interim Chief Scientific Officer, effective immediately (the “Pierce Transition”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465922068958/0001104659-22-068958-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.